Trevena (TRVN) PT Bumped to $14 at Cowen as TRV130 Shows Strong Safety And Efficacy Profile

Cowen analyst Ritu Baral reiterated an Outperform rating and bumped her price target on Trevena (NASDAQ: TRVN) to $14.00 (from $13.00) based on increased conviction around TRV130, which yesterday showed more positive Ph2b data (stat sig vs. PBO) in postoperative soft tissue pain (post-abdominoplasty).

"Data showed comparable efficacy, quicker onset of action, stat sig superior safety compared to morphine. We expect Ph3 development to begin in 1Q16," Baral commented.

For an analyst ratings summary and ratings history on Trevena click here. For more ratings news on Trevena click here.

Shares of Trevena closed at $6.00 yesterday.

You May Also Be Interested In

• Wells Fargo Upgrades Datadog (DDOG) to Overweight
• Piper Sandler Upgrades BlackLine (BL) to Neutral
• Wolfspeed (WOLF) PT Lowered to $30 at Deutsche Bank